TITLE

New FDA Approvals

PUB. DATE
January 2008
SOURCE
Drug Formulary Review;Jan2008, Vol. 24 Issue 1, Special section p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the drugs recently approved by the U.S. Food and Drug Administration (FDA). The agency has approved Tasigna® nolotinib capsules from Novartis for the treatment of Philadelphia chromosome positive chronic myeloid leukemia. The FDA has also granted approval for Nexavar® (sorafenib) from Bayer for patients with inoperable hepatocellular carcinoma. It relates how the drugs' effectiveness were assessed.
ACCESSION #
28161521

 

Related Articles

  • Novartis: Tasigna receives its first US approval for leukemia.  // PharmaWatch: Cancer;Dec2007, Vol. 6 Issue 12, p4 

    The article reports that the U.S. Food and Drug Administration has approved Tasigna from Novartis AG as second-line therapy for chronic myeloid leukemia (CML). This approval enables the company to dominate the CML market across multiple lines of therapy. The drug is an orally available Bcr-Abl...

  • Gleevec receives additional FDA approval in treatment of leukemia.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p37 

    Announces that the United States Food and Drug Administration has granted Novartis AG accelerated approval for Gleevec in the treatment of pediatric patients with a rare form of leukemia. Accelerated approval initially granted to Gleevec for the treatment of chronic myeloid leukemia.

  • Novartis: Tasigna receives its first US approval for leukemia.  // PharmaWatch: Monthly Review;Dec2007, Vol. 6 Issue 12, p6 

    The article reports on the approval of Tasigna from Novartis International AG as second-line therapy for chronic myeloid leukemia (CML) by the U.S. Food and Drug Administration (FDA). FDA also approved the company's drug Gleevec for CML treatment which would lead Novartis to continue dominating...

  • Tasigna.  // Pharmaceutical Representative;Aug2010, Vol. 40 Issue 8, p11 

    The article reports that the Tasigna of Novartis AG, which will be used to treat rare blood cancer is approved by the Food and Drug Administration (FDA) in the U.S.

  • Innovative Novartis Flu Vaccine OK'd.  // Chain Drug Review;12/17/2012, Vol. 34 Issue 21, p91 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of the first seasonal flu vaccine Flucelvax developed by Novartis AG using animal cell technology for prevention of influenza in people aged 18 and above.

  • Pharma: Other News To Note.  // BioWorld Today;2/20/2013, Vol. 24 Issue 33, p9 

    The article reports that the Food and Drug Administration (FDA) has approved the Novartis AG's mTOR inhibitor Zortress drug for the prophylaxis of organ rejection in adults receiving liver transplants.

  • New indication supports pediatric use of Gleevec.  // Drug Topics;6/2/2003, Vol. 147 Issue 11, p5 

    Reports on the Food and Drug Administration's approval for the drug imatinib from Norvatis in Philadelphia, Pennsylvania. Test on the efficacy and safety of the drug; Indications of imatinib.

  • Pharma: Other News To Note.  // BioWorld Today;11/26/2012, Vol. 23 Issue 228, p5 

    The article reports that the U.S. Food and drug Administration (FDA) has granted Novartis AG clearance for marketing of its vaccine Flucelvax in the U.S.

  • Zortress for organ rejection.  // Monthly Prescribing Reference;Jun2010, Vol. 26 Issue 6, pA.18 

    The article reports that the Food and Drug Administration (FDA) approved the use of everolimus tablets Zortress from Novartis AG to prevent rejection the of kidney transplant in adult patients in the U.S.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics